Sam Brusco, Associate Editor08.01.23
Etiometry, a company focused on clinical decision-support software, has gained U.S. Food and Drug Administration (FDA) clearance for its IVCO2 Index for use with neonatal ICU patients under 2 kg, who are especially vulnerable to effects of hypercapnia.
The IVCO2 Index integrates multiple data sources to generate an individualized assessment for ventilation-perfusion mismatch and spot the likelihood of a PaCO2 of over 50 mmHg in mechanically ventilated patients. It was engineered to overcome the challenges of conventional monitoring, like arterial blood gas testing and transcutaneous monitoring for tiny premature newborns.
“The IVCO2 Index is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients,” Dimitar Baronov, CTO of Etiometry told the press. “It allows clinicians to prioritize care for patients who need it most.”
Vigilant monitoring for hypercapnia is integral for maximizing neurodevelopmental outcomes and preventing complications. Digital monitoring illuminates the patient's condition between routine blood gas testing, adding another layer of protection to prevent oversights that may lead to poor outcomes.
“Our proprietary algorithm’s accurate and continuous monitoring for hypercapnia will enable the expansion of improved outcomes achieved by Etiometry partners within cardiac ICUs and PICUs into the NICU environment,” said Shane Cook, CEO of Etiometry.
The IVCO2 Index integrates multiple data sources to generate an individualized assessment for ventilation-perfusion mismatch and spot the likelihood of a PaCO2 of over 50 mmHg in mechanically ventilated patients. It was engineered to overcome the challenges of conventional monitoring, like arterial blood gas testing and transcutaneous monitoring for tiny premature newborns.
“The IVCO2 Index is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients,” Dimitar Baronov, CTO of Etiometry told the press. “It allows clinicians to prioritize care for patients who need it most.”
Vigilant monitoring for hypercapnia is integral for maximizing neurodevelopmental outcomes and preventing complications. Digital monitoring illuminates the patient's condition between routine blood gas testing, adding another layer of protection to prevent oversights that may lead to poor outcomes.
“Our proprietary algorithm’s accurate and continuous monitoring for hypercapnia will enable the expansion of improved outcomes achieved by Etiometry partners within cardiac ICUs and PICUs into the NICU environment,” said Shane Cook, CEO of Etiometry.